ORION CORPORATION

Orion Corporation and Aitia collaborate to develop Gemini Digital Twins for cancer drug discovery, leveraging Aitia's Causal AI and Orion's oncology expertise. The partnership aims to accelerate novel therapy development, with Orion having exclusive rights to identified drug targets and Aitia eligible for over USD 10 million in milestone payments per target.

Darolutamide plus ADT significantly reduced the risk of radiological progression or death by 46% in patients with metastatic hormone-sensitive prostate cancer (mHSPC), with consistent benefits across subgroups. Treatment emergent adverse events were low and similar between groups. The ARANOTE trial results were presented at the 2024 ESMO Congress and published in The Journal of Clinical Oncology, supporting the potential of darolutamide as a foundational therapy in prostate cancer.

Bayer's darolutamide plus ADT reduced radiological progression or death risk by 46% in mHSPC patients, with positive data both with and without docetaxel. The results were presented at the 2024 ESMO Congress and published in The Journal of Clinical Oncology. Bayer plans to submit the ARANOTE trial data to health authorities for expanded darolutamide use in mHSPC.

NUBEQA® (darolutamide) plus ADT showed a 46% reduction in risk of progression or death in the Phase III ARANOTE trial for metastatic hormone-sensitive prostate cancer (mHSPC), with no new safety signals observed. Results were published in The Journal of Clinical Oncology.

NUBEQA® (darolutamide) plus androgen deprivation therapy (ADT) significantly improved radiological progression-free survival (rPFS) in the Phase III ARANOTE trial for metastatic hormone-sensitive prostate cancer, reducing the risk of progression or death by 46% (HR 0.54; 95% CI 0.41-0.71; P<0.0001) compared to placebo plus ADT. The results were consistent with NUBEQA's established safety profile, with no new safety signals observed.